|Day Low/High||2.39 / 2.40|
|52 Wk Low/High||0.00 / 0.00|
Several stocks trading under $10 were poised to move on above-average volume during Tuesday's session.
Biotech watchdog Adam Feuerstein answers readers' questions about NexMed, Cell Therapeutics and other news-worthy stocks.
Exact recaptures Wall Street's interest as the firm gets closer to developing a commercially successful screening test for colon cancer.
Several stocks trading near $5 were poised to move on above-average volume during Friday's session.
A look back at 2009's best- and worst-performing bitoech stocks.
Small-caps and underdogs often outperform as the calendar flips over -- here's how you can take advantage.
Several stocks trading near $5 were poised to move on above-average volume during Thursday's session.
Several stocks trading under $10 -- including Sequenom, Avanir and Netlist -- were poised to move on above-average volume during Wednesday's session.
Several stocks trading under $5 were poised to move on above-average volume during Monday's session.
Several stocks trading under $10 were poised to move on above-average volume during Monday's session.
Sequenom's 3rd-quarter loss widens on higher expenses, lower revenue
Several small-cap stocks were moving on above-average volume during Thursday's session.
Company is delaying partnership talks for inhaled insulin product.
Epratuzumab data won't be presented at next week's rheumatology meeting.
Walgreen, Gannett, Warner Music Group, Sequenom, CIT Group are among big market movers Tuesday
Sequenom shares dive after CEO, other execs fired after mishandling of medical test results
Launching a successful prenatal genetic test for Down syndrome may be beyond Sequenom's reach.
An investigation of Sequenom's study methods finds the firm's data was unreliable and misreported, leading to an executive purging.
Cramer loves the packaging space, especially Crown Holdings, which he calls a winner.
Cramer says investors should pay more attention on the swine-flu trade than Obama's health care overhaul. Click for news from Jim Cramer.
Concerned about safety, panel asks for another trial to be conducted
Traders are placing bullish bets on Kraft Foods and biotech firm Sequenom, OptionMonster says.
Bullish traders are expecting positive news about Sequenom's Down Syndrome test.
Geron, Oculus, BioSante, Gilead Sciences and Sequenom are among readers' stocks of interest in this special edition mailbag.
Vanda Pharmaceuticals can't find a buyout partner; Oculus Innovative Sciences backs off drug claims; Sequenom walks back expectations for its Downs syndrome gene test.
July and August are traditionally slow months on the biotech calendar. But not this year as biotech firms, both big and small, release results from clinical trials or await FDA decisions.
Here's a look at the charts of Nasdaq stocks such as Cheesecake Factory and BioCryst.
Bullish traders are jumping on CB Richard Ellis stock and options after a hedge fund said it would buy shares.
Sequenom options were active Tuesday with more than 86,000 calls traded, dwarfing the average call turnover of 2,600 in the last month.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.